These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 33981582

  • 1. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
    Yamamoto R, Yoden E, Tanaka N, Kinoshita M, Imakiire A, Hirato T, Minami K.
    Mol Genet Metab Rep; 2021 Jun; 27():100758. PubMed ID: 33981582
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO® I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)].
    Yamamoto R, Kawashima S.
    Nihon Yakurigaku Zasshi; 2022 Jun; 157(1):62-75. PubMed ID: 34980815
    [Abstract] [Full Text] [Related]

  • 3. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R, Martins AM, So S, Yamamoto T, Yamaoka M, Ikeda T, Tanizawa K, Sonoda H, Schmidt M, Sato Y.
    Mol Ther; 2021 Jul 07; 29(7):2378-2386. PubMed ID: 33781915
    [Abstract] [Full Text] [Related]

  • 4. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
    Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, Ikeda T, So S, Tanizawa K, Sonoda H, Sato Y.
    Mol Ther; 2021 Feb 03; 29(2):671-679. PubMed ID: 33038326
    [Abstract] [Full Text] [Related]

  • 5. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
    Giugliani R, Martins AM, Okuyama T, Eto Y, Sakai N, Nakamura K, Morimoto H, Minami K, Yamamoto T, Yamaoka M, Ikeda T, So S, Tanizawa K, Sonoda H, Schmidt M, Sato Y.
    Int J Mol Sci; 2021 Oct 10; 22(20):. PubMed ID: 34681597
    [Abstract] [Full Text] [Related]

  • 6. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
    Imakiire A, Morimoto H, Suzuki H, Masuda T, Yoden E, Inoue A, Morioka H, Konaka T, Mori A, Shirasaka R, Kato R, Hirato T, Sonoda H, Minami K.
    Mol Pharm; 2023 Nov 06; 20(11):5901-5909. PubMed ID: 37860991
    [Abstract] [Full Text] [Related]

  • 7. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.
    Nakamura K, Sakai N, Hossain MA, Eisengart JB, Yamamoto T, Tanizawa K, So S, Schmidt M, Sato Y.
    Orphanet J Rare Dis; 2024 Mar 07; 19(1):104. PubMed ID: 38454486
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
    Morimoto H, Morioka H, Imakiire A, Yamamoto R, Hirato T, Sonoda H, Minami K.
    Mol Ther Methods Clin Dev; 2022 Jun 09; 25():534-544. PubMed ID: 35662814
    [Abstract] [Full Text] [Related]

  • 9. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
    Tomita K, Okamoto S, Seto T, Hamazaki T, So S, Yamamoto T, Tanizawa K, Sonoda H, Sato Y.
    JIMD Rep; 2021 Nov 09; 62(1):9-14. PubMed ID: 34765392
    [Abstract] [Full Text] [Related]

  • 10. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
    Morimoto H, Kida S, Yoden E, Kinoshita M, Tanaka N, Yamamoto R, Koshimura Y, Takagi H, Takahashi K, Hirato T, Minami K, Sonoda H.
    Mol Ther; 2021 May 05; 29(5):1853-1861. PubMed ID: 33508431
    [Abstract] [Full Text] [Related]

  • 11. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD, Smolov MA, Lyagoskin IV, Degterev MB, Rechetnik EV, Rodionov AV, Pantyushenko MS, Shukurov RR.
    BioDrugs; 2023 May 05; 37(3):375-395. PubMed ID: 37014547
    [Abstract] [Full Text] [Related]

  • 12. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A, Tachibana K, Hirato T, Takahashi K.
    Mol Ther; 2018 May 02; 26(5):1366-1374. PubMed ID: 29606503
    [Abstract] [Full Text] [Related]

  • 13. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, Yamaoka M, Tachibana K, Hirato T, Sato Y.
    Mol Ther; 2019 Feb 06; 27(2):456-464. PubMed ID: 30595526
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N, Kida S, Kinoshita M, Morimoto H, Shibasaki T, Tachibana K, Yamamoto R.
    Mol Genet Metab; 2018 Sep 06; 125(1-2):53-58. PubMed ID: 30064964
    [Abstract] [Full Text] [Related]

  • 15. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
    Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM.
    Biotechnol Bioeng; 2014 Nov 06; 111(11):2317-25. PubMed ID: 24889100
    [Abstract] [Full Text] [Related]

  • 16. Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy.
    Vollebregt AAM, Hoogeveen-Westerveld M, Ruijter GJ, van den Hout H, Oussoren E, van der Ploeg AT, Pijnappel WWMP.
    J Pediatr; 2022 Sep 06; 248():100-107.e3. PubMed ID: 35568060
    [Abstract] [Full Text] [Related]

  • 17. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
    Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.
    Drug Metab Dispos; 2012 Feb 06; 40(2):329-35. PubMed ID: 22065691
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H, Chung JK, Mascelli MA, McCauley TG.
    PLoS One; 2015 Feb 06; 10(4):e0122453. PubMed ID: 25836678
    [Abstract] [Full Text] [Related]

  • 19. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY, Lee J, Ko AR, Kwak MJ, Kim S, Sohn YB, Park SW, Jin DK.
    Orphanet J Rare Dis; 2015 Oct 31; 10():141. PubMed ID: 26520066
    [Abstract] [Full Text] [Related]

  • 20. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
    Harmatz P, Giugliani R, Martins AM, Hamazaki T, Kubo T, Kira R, Minami K, Ikeda T, Moriuchi H, Kawashima S, Takasao N, So S, Sonoda H, Hirato T, Tanizawa K, Schmidt M, Sato Y.
    Mol Ther; 2024 Mar 06; 32(3):609-618. PubMed ID: 38204164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.